A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC).

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2013

At a glance

  • Drugs Viagenpumatucel-L (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Sponsors Heat Biologics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 20 Nov 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top